TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company focused on the development and commercialization of new inhalation products for the treatment of chronic respiratory diseases and lung conditions.
In early testing the Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubility.
Jan 11, 2021 6:00 AM EST: TFF Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
TFF Pharmaceuticals Corporate Overview – March 2020
January 7, 2021
TFF Pharmaceuticals Announces First Dosing of Asthma Patients with Voriconazole Inhalation Powder in a Phase 1b Clinical Trial
December 15, 2020
November 12, 2020